L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 5.42 NOK 4.63% Market Closed
Market Cap: 370m NOK
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LYTIX Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast LYTIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYTIX is 14.28 NOK with a low forecast of 14.14 NOK and a high forecast of 14.7 NOK.

LYTIX Lowest Forecast
Wall Street Target
14.14 NOK
161% Upside
LYTIX Average Forecast
Wall Street Target
14.28 NOK
163% Upside
LYTIX Highest Forecast
Wall Street Target
14.7 NOK
171% Upside
Lowest
Price Target
14.14 NOK
161% Upside
Average
Price Target
14.28 NOK
163% Upside
Highest
Price Target
14.7 NOK
171% Upside
Lytix Biopharma AS Competitors:
Price Targets
P
214450
PharmaResearch Co Ltd
8% Downside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
2% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
2% Downside
ADMA
ADMA Biologics Inc
18% Upside
P
214450
PharmaResearch Co Ltd
8% Downside
S
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
2% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
2% Downside
ADMA
ADMA Biologics Inc
18% Upside
REGN
Regeneron Pharmaceuticals Inc
49% Upside
KMDA
Kamada Ltd
125% Upside
300685
Amoy Diagnostics Co Ltd
40% Upside
EDIT
Editas Medicine Inc
148% Upside

Revenue
Forecast

Revenue Estimate
Lytix Biopharma AS

For the last 5 years the compound annual growth rate for Lytix Biopharma AS's revenue is 64%. The projected CAGR for the next 2 years is 423%.

64%
Past Growth
423%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
LYTIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYTIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYTIX stock valuation using valuation multiples.
Wall Street Estimates
LYTIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYTIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYTIX's stock price target?
Price Target
14.28 NOK

According to Wall Street analysts, the average 1-year price target for LYTIX is 14.28 NOK with a low forecast of 14.14 NOK and a high forecast of 14.7 NOK.

What is Lytix Biopharma AS's Revenue forecast?
Projected CAGR
423%

For the last 5 years the compound annual growth rate for Lytix Biopharma AS's revenue is 64%. The projected CAGR for the next 2 years is 423%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 249,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.